Home

Person

Douglas Hanahan

This person has left EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (59)

Page 3 of 3

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Douglas Hanahan, Anguraj Sadanandam

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically 6 months from diagnosis(1). Numerous phase 3 trials of agents effective in other malignancies have failed to benefit unselected PDA populations, although patients do ...

Nature Publishing Group2011

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

Douglas Hanahan

Mutationally corrupted cancer (stem) cells are the driving force of tumor development and progression. Yet, these transformed cells cannot do it alone. Assemblages of ostensibly normal tissue and bone marrow-derived (stromal) cells are recruited to constit ...

Elsevier2012

A New Twist on Radiation Oncology: Low-Dose Irradiation Elicits Immunostimulatory Macrophages that Unlock Barriers to Tumor Immunotherapy

Michele De Palma, Douglas Hanahan, George Coukos

Tumor-infiltrating macrophages typically promote angiogenesis while suppressing antitumoral T cell responses. In this issue of Cancer Cell, Klug and colleagues report that clinically-feasible, low-dose irradiation redirects macrophage differentiation from ...

Elsevier2013

Bioavailable copper modulates oxidative phosphorylation and growth of tumors

Johan Auwerx, Douglas Hanahan, Carole Poitry-Yamate, Pénélope Andreux, Seiko Ishida

Copper is an essential trace element, the imbalances of which are associated with various pathological conditions, including cancer, albeit via largely undefined molecular and cellular mechanisms. Here we provide evidence that levels of bioavailable copper ...

National Academy of Sciences2013

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

Douglas Hanahan, Elizabeth Anne Allen

Purpose: Preclinical trials of a mouse model of pancreatic neuroendocrine tumors (PNET) were conducted to determine whether dual FGF/VEGF pathway inhibition with brivanib can improve first-line efficacy in comparison with VEGF inhibitors lacking fibroblast ...

American Association for Cancer Research2011

Roadmap for the Emerging Field of Cancer Neuroscience

Douglas Hanahan

Mounting evidence indicates that the nervous system plays a central role in cancer pathogenesis. In turn, cancers and cancer therapies can alter nervous system form and function. This Commentary seeks to describe the burgeoning field of "cancer neuroscienc ...

CELL PRESS2020

Rethinking the war on cancer

Douglas Hanahan

Some 40 years ago a metaphor was posed that cancer was such an insidious adversary that a declaration of war on the disease was justified. Although this statement was a useful inspiration for enlistment of resources, despite extraordinary progress in our u ...

Elsevier2014

Unsorted single-cell RNA sequencing profiles of metastatic melanoma patients reveal the heterogeneity of melanoma-associated fibroblasts

Douglas Hanahan, Krisztian Homicsko, Marco Matter

OXFORD UNIV PRESS2019

The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity

Douglas Hanahan, Mélanie Louise Tichet, Stephan Wullschleger

AMER ASSOC CANCER RESEARCH2021

Douglas Hanahan

Graph Chatbot

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

A New Twist on Radiation Oncology: Low-Dose Irradiation Elicits Immunostimulatory Macrophages that Unlock Barriers to Tumor Immunotherapy

Bioavailable copper modulates oxidative phosphorylation and growth of tumors

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

Roadmap for the Emerging Field of Cancer Neuroscience

Rethinking the war on cancer

Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma

Hallmarks of cancer: applications to cancer medicine?

Hallmarks Of Cancer: A 2012 Perspective

Unsorted single-cell RNA sequencing profiles of metastatic melanoma patients reveal the heterogeneity of melanoma-associated fibroblasts

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy

Co-targeting autophagy, macrophages and vasculature in glioma tumors triggers tumor immunity

Colorectal cancer classification based on gene expression is not associated with FOLFIRI response Reply

Co-targeting distinct hallmark capabilities for therapeutic benefit in pre-clinical GBM models

The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity

Towards a Cancer Mission in Horizon Europe

A personalised approach for anti-GITR-based immunotherapy in preclinical models of pancreatic ductal adenocarcinoma

Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients